CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

Part of paid clinical trials in Valhalla, New York.

Sponsor
New York Medical College
Study ID
NCT06617286
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Classical Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
6 Years - 29 Years
Healthy Volunteers
Not accepted

Interventions

  • CD30 CAR T-cell — BIOLOGICAL
    After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.

Study Details

Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.

Key Dates

Start date
Dec 1, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2039
Completion
Dec 31, 2040

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CD30 CAR T-cells
    Patients will receive autologous CD30 CAR T-cells post autologous stem cell transplant between days 21-42.

Primary Outcome Measure

Safety of administering CAR T-cells [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New York Medical CollegeValhallaNew York10595
Mitchell S Cairo, MD
[email protected]
914-594-2150

Find similar trials in Valhalla, NY

By research site
New York Medical College· Valhalla, NY

Related Studies